BREAKING NEWS: FDA advisory committee votes NOT to recommend approval of booster shots for Pfizer’s Covid vaccine
- FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) Voted Not to Recommend Approval of Covid Vaccine Booster Shots
- The panel said there was insufficient evidence that a third dose was safe and effective for use
- Pfizer said data suggests that the efficacy of two doses decreases from 96.2% to 83.7% after six months, but that a third dose increases antibody levels
- FDA officials have previously expressed doubts about the need for additional doses, saying the vaccines are still highly effective against serious illness and death
An independent panel of the U.S. Food and Drug Administration (FDA) voted 16-2 not to recommend approval of booster doses for the Pfizer-BioNTech COVID-19 vaccine.
The Advisory Committee on Vaccines and Related Biological Products (VRBPAC) said there was insufficient evidence that a third dose was safe and effective for use at least six months after the last dose.
The FDA is not obligated to follow the advisory group’s recommendations, but the panel that advises against approval makes it harder for the agency to justify progress.
Pfizer has submitted data that the company says shows that the vaccine’s effectiveness decreases by about six percent two months after the second and final dose.
But many scientists, including senior FDA officials, disagree, claiming the vaccines are still highly effective at preventing serious illness and death.
The Advisory Committee on Vaccines and Related Biological Products (VRBPAC) voted not to recommend the approval of the booster shots for the COVID-19 vaccine. Pictured: A nurse administers a COVID-19 booster injection to Lana Sellers in Altamonte Springs, Florida, Aug. 18
This is a latest news item and will be updated.